Solo
I'm flattered that you would want to hear what I think of Telomolecular but to be truthful I've got my hands full trying to keep up with all what Geron has going.
I would be careful of any company trying to get into Telomerase without an agreement with Geron. Geron has controlling IP on Telomerase and will bite back if encroached upon.
Although I will sound like Micro the development period for new biotechnology approaches usually takes a lot more time and money than you might hope for, often driven by the FDA requiring extremely thorough testing. Think 2,500+ spinal injured rats.
All of this time consuming research without revenue has to be supported with massive amounts of cash raised from sources that may ultimately take over the company or run it into the ground through naked shorting. Most institutional investors will avoid a company with potential substantial revenue years in the future.
I've been heavily into Geron for almost ten years, and even with fantastic possibilities and excellent progress everything they have achieved has taken twice the time I expected. At times they were almost dead and ultimately were saved by the first results on GRNVAC1. The stock hit a low of $1.41 but shortly before it hit that number I bought quite a bit at $1.78 because one of my well informed chat group collegues had heard the results were stronger than most expected.
This reinforces the point about doing the best DD you can, and if you really feel the company is on solid ground then hang tough with it.
Early stage biotech, especially if financed on a shoe string is a very risky business.
Good Luck
Bob
News 
Market Data 
Discover 
